Goldman Sachs Physical Gold ETF vs Becton Dickinson and Co — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.47, while Becton Dickinson and Co trades at $181.29 (market cap $48.93B). The key difference: Becton Dickinson and Co pays a 2.34% dividend while Goldman Sachs Physical Gold ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | BDX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $185.39 |
52-Week Low | $32.74 | $138.62 |
Market Cap | — | $48.93B |
Enterprise Value | — | $65.03B |
Dividend Yield | — | 2.34% |
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused asset, trades at $42.81, up 2.22% in the past 24 hours. Technical indicators show a bullish overall signal with strong moving average support, though oscillators suggest caution due to overbought RSI levels. Recent news highlights gold's rebound potential, with analysts citing supportive factors like central bank buying and easing Fed expectations as catalysts for further price appreciation.
The outlook for AAAU remains positive, driven by gold's strategic role amid geopolitical and fiscal uncertainties. Key risks include potential Fed policy shifts and market volatility, but institutional accumulation and bullish analyst forecasts indicate sustained investor confidence in gold's upward trajectory.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →